- Phare
- Validé par KD/KO
Anticorps Monoclonal anti-MGMT
MGMT Monoclonal Antibody for WB, IF/ICC, FC (Intra), ELISA
Hôte / Isotype
Mouse / IgG2a
Réactivité testée
Humain et plus (1)
Applications
WB, IF/ICC, FC (Intra), ELISA
Conjugaison
Non conjugué
CloneNo.
1H2C9
N° de cat : 67476-1-Ig
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules U2OS, cellules A549, cellules HeLa, cellules HepG2, cellules Jurkat, cellules LNCaP, cellules MCF-7, cellules MOLT-4, cellules Raji |
| Résultats positifs en IF/ICC | cellules HepG2, |
| Résultats positifs en FC (Intra) | cellules Jurkat, |
Dilution recommandée
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:5000-1:50000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| WB | See 2 publications below |
| IF | See 2 publications below |
Informations sur le produit
67476-1-Ig cible MGMT dans les applications de WB, IF/ICC, FC (Intra), ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | Humain, souris |
| Hôte / Isotype | Mouse / IgG2a |
| Clonalité | Monoclonal |
| Type | Anticorps |
| Immunogène | MGMT Protéine recombinante Ag29936 |
| Nom complet | O-6-methylguanine-DNA methyltransferase |
| Masse moléculaire calculée | 22 kDa |
| Poids moléculaire observé | 22 kDa |
| Numéro d’acquisition GenBank | BC000824 |
| Symbole du gène | MGMT |
| Identification du gène (NCBI) | 4255 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine A |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
MGMT is the primary vehicle for cellular removal of alkyl lesions from the O-6 position of guanine and the O-4 position of thymine. While key to the maintenance of genomic integrity, MGMT also removes damage induced by alkylating chemotherapies, inhibiting the efficacy of cancer treatment [PMID:23065697].MGMT is the primary mechanism for the removal of alkylation damage from the O-6 position of guanine [PMID: 17482892]. The O-6 position of guanine is one of several positions in DNA bases to which alkyl groups are attached in SN1 alkylation reactions, and this repair has been well-characterized in mammalian cells and via MGMT homologs in bacteria and Archaea.[PMID: 10767620]
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for MGMT antibody 67476-1-Ig | Download protocol |
| IF protocol for MGMT antibody 67476-1-Ig | Download protocol |
| FC protocol for MGMT antibody 67476-1-Ig | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Nucleic Acids Res KDM6B promotes PARthanatos via suppression of O6-methylguanine DNA methyltransferase repair and sustained checkpoint response. | ||
Cancer Discov Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma | ||
J Colloid Interface Sci Brain-targeted polymersomes mediating RNAi of STAT3 sensitize glioblastoma to temozolomide and immunotherapy |




